Biotechnology News

Browse the latest Biotechnology news. Use the menu or navigation tiles to change industry or topic.

January 22, 2026 07:00 ET | Source: Rentschler Biopharma SE

Rentschler Biopharma appoints Detra Glinatsis as Head of Business Development U.S.

LAUPHEIM, Germany and MILFORD, Mass., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals,...
January 22, 2026 07:00 ET | Source: Vivani Medical, Inc.

Vivani Subsidiary Cortigent to Present Orion System’s Advanced Brain Implant Technology in Poster Session at NANS 2026

Cortigent is a leading developer of brain interface devices based on precision neurostimulation technology The company’s new Orion cortical stimulation system for visual perception, designed to...
January 22, 2026 06:00 ET | Source: Greenwich LifeSciences, Inc.

Greenwich LifeSciences Announces FDA Approves Use of Commercially Manufactured GP2 in FLAMINGO-01

STAFFORD, Texas, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
January 22, 2026 03:00 ET | Source: PulseSight Therapeutics S.A.S

Dosing completed in the Phase I clinical trial of PulseSight Therapeutics’ PST-611 treatment for dry AMD/Geographic Atrophy (GA)

PARIS, Jan. 22, 2026 (GLOBE NEWSWIRE) -- PulseSight Therapeutics SAS, an ophthalmology clinical stage biotech company developing disruptive vectorized gene therapies with minimally-invasive delivery...
January 21, 2026 20:54 ET | Source: Erasca, Inc.

Erasca Announces Pricing of Upsized Public Offering of Common Stock

SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...
January 21, 2026 12:05 ET | Source: Society For Science

Nation’s Top 40 High School Scientists to Compete for $1.8 Million in Awards at the Prestigious Regeneron Science Talent Search

Society for Science & Regeneron announced the finalists in the Regeneron Science Talent Search, the nation's oldest and most prestigious STEM competition
January 21, 2026 12:00 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics salue l'octroi de la désignation de médicament orphelin par la FDA du pegrizprument (VEL-101)

OSE Immunotherapeutics salue l'octroi de la désignation de médicament orphelin par la FDA du pegrizprument (VEL-101) Nantes, le 21 janvier, 18 heures - OSE Immunotherapeutics SA (ISIN: FR0012127173;...
January 21, 2026 12:00 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101)

OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101)
January 21, 2026 09:00 ET | Source: Human Continuum Inc.

Human Continuum Appoints Dr. Tsun “Sean” Law MD, MBA as its Chief Executive Officer to Lead the Research and Development Efforts Focused on Next-Generation Exosome Therapies and Over-the-Counter Exosome-based Products

New York, N.Y., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Human Continuum Inc. (“HC” or “the Company”), a developer of platelet-derived and plant-based exosome therapeutics and diagnostics, today announced...
January 21, 2026 08:45 ET | Source: Actuate Therapeutics

Actuate Therapeutics Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet into a Phase 1/2 Clinical Program in Refractory Cancers

-Initiation of phase 1 portion of the trial planned in 2H 2026 -Phase 2 portion of the trial will initiate development of the elraglusib tablet in specific indications, including refractory melanoma...